Who is eligible for clinical trial NCT07146906?

Participants must meet the protocol's inclusion criteria for Immunoglobulin A Nephropathy (IgAN). The stated age range is 18 Years to 100 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07146906 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-06

A Study to Assess the Effects of Zigakibart on IgA Nephropathy. (NCT07146906)

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (9 items).

Location: Colorado Kidney Care Nephrology — Denver, Colorado

Age range: 18 Years to 100 Years

🧪 Interventions in This Study

zigakibart (BIOLOGICAL)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Primary IgAN, confirmed by kidney biopsy, within 5 years prior to Screening
eGFR ≥45 mL/min/1.73 m2, based on the 2021 CKD-EPI equation, at Screening
Persistent proteinuria, defined as either
Total Urine Protein ≥0.5 g/day or UPCR ≥0.5 g/g in a 24-hour urine collection, at Screening, despite maximally tolerated dose or poorly tolerated supportive therapy or
IgAN diagnosis \<6 months prior to Screening with Total Urine Protein \>1.5 g/day or UPCR \>1.5 g/g in a 24-hour urine collection, at the time of clinical presentation or diagnosis
Body weight ≥45 kg and body mass index (BMI) ≤35.0 kg/m2, at Screening

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Secondary forms of IgAN, as determined by the Investigator, diagnosis of IgA vasculitis, or any other nephropathy or chronic urinary tract disorder
Total IgG \<6.0 g/L at screening
Any chronic urinary tract disorder, including but not limited to retention, incontinence, and/or recurrent urinary tract infections
An average systolic blood pressure \>150 mmHg or average diastolic blood pressure \>90 mmHg based on three measurements at Screening
Treatment with complement pathway inhibitors, mycophenolic acids, systemic calcineurin inhibitors or corticosteroids, immunosuppressive or immunomodulatory agents within 12 months prior to screening
Acute kidney injury (AKI), defined by AKI network criteria, within 4 weeks prior to screening
Current treatment with anti-APRIL monoclonal antibodies or dual APRIL/BAFF inhibitors or past treatment of the same at any time for \>3 consecutive months prior to screening
Planned initiation of, or recently (within 24 weeks) initiated, treatment with glucagon-like peptide-1 agonists at screening Other protocol-defined inclusion/exclusion criteria may apply.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

Colorado Kidney Care Nephrology — Denver, Colorado
American Clinical Trials — Acworth, Georgia
Univ Of Iowa Hospitals And Clinics — Iowa City, Iowa
Inter Med Consultants — Edina, Minnesota
Novartis Investigative Site — Serra, Espírito Santo
Novartis Investigative Site — Recife, Pernambuco
Novartis Investigative Site — Natal, Rio Grande do Norte
Novartis Investigative Site — Botucatu, São Paulo
Novartis Investigative Site — Beijing,
Novartis Investigative Site — Shanghai,
Novartis Investigative Site — Prague,
Novartis Investigative Site — Munich, Bavaria
Novartis Investigative Site — Hanover,
Novartis Investigative Site — Mainz,
Novartis Investigative Site — Ranica, BG
Novartis Investigative Site — Brescia, BS
Novartis Investigative Site — Pavia, PV
Novartis Investigative Site — Kawasaki, Kanagawa
Novartis Investigative Site — Miyazaki,
Novartis Investigative Site — Lodz,
Novartis Investigative Site — Opole,
Novartis Investigative Site — Seoul, Seoul
Novartis Investigative Site — Seoul,
Novartis Investigative Site — Pamplona, Navarre
Novartis Investigative Site — Valencia, Valencia

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Immunoglobulin A Nephropathy (IgAN)

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) — Little Rock, Arkansas

Explore by condition: All Immunoglobulin A Nephropathy (IgAN) clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗